Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients - Wikidata - wikimedia - TriplyDB

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

http://www.wikidata.org/entity/Q24602593

about

HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa Novel directions in HIV-1 vaccines revealed from clinical trials Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study.Comparison of Major and Minor Viral SNPs Identified through Single Template Sequencing and Pyrosequencing in Acute HIV-1 Infection.An HIV Vaccine for South-East Asia-Opportunities and Challenges.Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda Opportunities and challenges for cost-efficient implementation of new point-of-care diagnostics for HIV and tuberculosis.Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection.The implementation and appraisal of a novel confirmatory HIV-1 testing algorithm in the Microbicides Development Programme 301 Trial (MDP301).HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene High HIV-1 prevalence, risk behaviours, and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria, Uganda.In pursuit of an HIV vaccine: designing efficacy trials in the context of partially effective nonvaccine prevention modalities Malaria diagnostics in clinical trials.Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.Recommendation of HIV test brings diagnostic dilemma home.First-in-Human Randomized Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.

P2860

Q28082836-8CA6C778-2037-4138-8325-2BD1D8C38BDA Q28654629-921D9229-3742-4CEB-9978-463DFA0182DB Q33645528-F1CBBC4F-B17F-4809-9AAA-C100FB4AC71B Q33813145-E8E6663D-CEB8-4A6E-9A2E-40B35474D689 Q33999615-8886AF53-11D3-4DC3-9527-8321A08A2273 Q34663554-CB77AFAD-0F65-4397-8C6F-2D3E159CBF0A Q35752023-54645AB0-EAF8-4158-9D27-06A0F86FD842 Q35759184-874ABB3C-EBEF-4E71-A463-3BE91395B15C Q35826681-92262D5A-E3F8-4438-A9A2-B48B40B890BF Q35863340-B40230FB-CE5A-4433-9627-BA6DCFF106A3 Q35907384-055D284B-9BAF-452B-93CA-E958145F03CA Q36106653-5F03FC48-48E3-408B-9648-51D60936F1D6 Q36226878-A2C65FD5-AE3B-435C-B22D-F683682DBDF9 Q36464748-4F42EF9C-936D-49A7-B6E6-692376DB9AFC Q36931790-6565B899-C1E3-4F5E-84B5-CF37CE1CB1BE Q37039342-6323A1BC-69FD-4F59-93A6-A0F2A614DF26 Q37258303-AEE0F46E-DB1E-4E5C-922A-59182FD94198 Q37287631-38ED2052-9EA9-41F7-9773-C26A03A8DEE8 Q37643303-834B0250-8510-4F5A-87D3-02A693954DBB Q50576393-BDE33388-E88E-41A4-A389-64C464C5589A Q52580309-040D450F-07F4-469B-840D-13A673A939DC

P2860

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

http://www.wikidata.org/entity/Q24602593

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@ast

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@en

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@nl

type

label

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@ast

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@en

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@nl

prefLabel

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@ast

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@en

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@nl

P1433

Q24602593-E4E372D3-FBBE-479B-8C85-41A6DC9C21FC

P1476

Q24602593-456C5914-5078-46E5-BF45-03FDF001B456

P2093

Q24602593-192E0C35-C286-4882-BD12-0F067639024E

Q24602593-3F0B4DE2-1B87-48D9-912E-427E4AF516C3

Q24602593-CD7E0B0C-67AB-4666-BC0A-8627385FFBAB

Q24602593-FD0F4584-ED93-4576-847D-7D1AF488C573

P2860

Q24602593-02E8CFF9-2156-46BA-A896-F40AC3392799

Q24602593-04050536-04F6-46C8-8CE6-F2812FAD128D

Q24602593-200F728D-9AD6-48E1-AEB5-E648CAB9EFA7

Q24602593-26AE552F-9FF9-427F-BE52-51E72160EF1B

Q24602593-286C0981-D0A3-4FCF-8009-B984751E1A9C

Q24602593-31A1715A-0756-483C-981D-701219A953C6

Q24602593-3D267A33-5316-46FE-8A1B-5E511048FD27

Q24602593-48E66C82-8120-4FDB-8DC2-FA449173F567

Q24602593-4A6FA985-8347-4CE9-BAB9-138A4D48F7BE

Q24602593-574DE2CE-C623-4D8E-8261-A257378F4D01

P304

Q24602593-3D368F32-03C8-4146-AC02-0248BF27B5E8

P31

Q24602593-3EFFAB30-C722-42DE-952C-04430B2342D0

P3181

Q24602593-AD4769D8-CEE0-46A6-A766-4CDFCB0680C5

P356

Q24602593-E326C0AF-120E-47E6-8FD5-0DAD17CBF6F4

P407

Q24602593-6290D6BD-506C-4926-9953-7A78430DB1F9

P433

Q24602593-D9800783-3A38-46A3-9E7A-A332CAC339B0

P478

Q24602593-19315AB1-886E-4DA6-B00F-2F90E82D7793

P50

Q24602593-7259A3C5-6197-457B-B6CC-1F0FE91B0750

P577

Q24602593-6422EEF2-54A4-4320-843C-9248FBC4B0D7

P5875

Q24602593-B455A78F-3779-4599-8C57-290D8D855333

P698

Q24602593-0349EB61-3847-48D0-B4BE-92C7DA200713

P932

Q24602593-5F5DD7E2-18E3-474B-8F5F-C57411D1591B

P3181

P356

P1433

Journal of the American Medical Association

P1476

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients

@en

P2093

Barbara Metch

http://www.w3.org/2001/XMLSchema#string

Cristine J Cooper

http://www.w3.org/2001/XMLSchema#string

Joan Dragavon

http://www.w3.org/2001/XMLSchema#string

Robert W Coombs

http://www.w3.org/2001/XMLSchema#string

P2860

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes

Multiple false reactions in viral antibody screening assays after influenza vaccination.

Challenges in the development of an HIV-1 vaccine.

Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

P304

275-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4025863

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.2010.926

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

304

http://www.w3.org/2001/XMLSchema#string

P50

Lindsey R Baden

P577

2010-07-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45271929

http://www.w3.org/2001/XMLSchema#string

P698

20639561

http://www.w3.org/2001/XMLSchema#string

P932

3086635

http://www.w3.org/2001/XMLSchema#string